Effect of empagliflozin on albuminuria, eGFR and serum creatinine: updated results from the ABCD national empagliflozin audit. Thomas SJ Crabtree¹, Alex Bickerton², Jackie Elliot³, Rajeev Raghavan⁴, Dennis Barnes⁵, Siva Sivappriyan⁶, Suzanne Phillips⁷, Alison Evans⁷, Devesh Sennik⁸, Anurita Rohilla⁹, Ian Gallen¹⁰, Robert EJ Ryder¹¹ on behalf of the  ABCD Empagliflozin Audit Contributors. British Journal of Diabetes Vol 21 14/04/2021

Due to the pressure on hospital teams during the COVID pandemic, we have postponed the 2021 competition but are launching a revamped award for 2022 which has been amended to take into account the current COVID situation. We are inviting colleagues to submit entries which will be for:

‘The Rowan Hillson Inpatient Safety Award – The best interventions: Redesigning, rebuilding and maintaining safe inpatient diabetes care during COVID’

In this first of a series of three webinars focussing on obesity, hosted by ABCD and GIRFT and supported by Novo Nordisk Ltd, Professor Carel le Roux will present strategies for preventing diabetes with intentional weight loss.

This is a Novo Nordisk Sponsored meeting

The Joint British Diabetes Societies (JBDS) for Inpatient Care group was created in 2008 to ‘deliver a set of diabetes inpatient guidelines and proposed standards of care within secondary care organisations’, with the overall aim of improving inpatient diabetes care through the development and use of high quality evidence based guidelines, and through better inpatient care pathways.

The National Inpatient Diabetes COVID19 Response Group has published guidance for healthcare professionals on managing hyperglycaemia/diabetes in a COVID Virtual Ward for patients with or without diabetes. This is to support safe management of hyperglycaemia in those receiving glucocorticoid treatment for COVID-19 infection outside of a hospital environment.

COncise adVice on Inpatient Diabetes (COVID:Diabetes): Hyperglycaemia/diabetes Guidance For People With COVID-19 Infections Managed In A Virtual Ward: A Guide For Healthcare Professionals

The use of technologies to monitor diabetes is expanding rapidly. The flash glucose monitoring (FSL) is allowed for clinical use in selected group of individuals with type 1 Diabetes in the UK. 

In GB, there are 1428 drivers with type 1 Diabetes who currently hold a Group 2 (lorry and bus) Driving licence. The regulation to allow insulin treated individuals with diabetes to drive, was allowed, several years ago when UK was an EU member.